Differential expression of matrix metalloproteinases and their inhibitors in human and mouse lung development

Summary

Lung development is a highly orchestrated process characterized by timed expression and activation of growth factor and protease/antiprotease systems. This interplay is essential in regulating vasculogenesis, alveolarization, and epithelial to mesenchymal transition during lung development. Alterations in the proteolytic/antiproteolytic balance of the lung have been associated with several respiratory diseases characterized by changes in the lung extracellular matrix (ECM). Here, we characterized the expression pattern of matrix metalloproteases (MMP) and their inhibitors, the tissue inhibitors of metalloproteases (TIMP), in human and mouse lung development. Using MMP/TIMP expression arrays, RT-PCR, Western Blotting, and ELISA analyses, we demonstrate that fetal human lung is characterized by a dominant proteolytic profile with high MMP-2 and little TIMP-3 expression. Adult human lung, in contrast, exhibits a more anti-proteolytic profile with decreased MMP-2 and increasedTIMP-3 expression. MMP-14, MMP-20,TIMP-1, and TIMP-2 were constitutively expressed, irrespective of the developmental stage. Similar results were obtained using mouse lungs of different developmental stages, with the addition that in mouse lung, TIMP-2 and TIMP-3 were upregulated as lung development progressed. Exposure of neonatal mice to chronic hypoxia (10% O₂), a stimulus that leads to an arrest of lung development, resulted in upregulation of MMP-2 with a concomitant downregulation of TIMP-2.These results provide a comprehensive analysis of MMP and TIMP expression during human and mouse lung development. MMP-2, TIMP-2, and TIMP-3 may be key regulatory enzymes during lung development, possibly through their complex action on ECM components, membrane receptor ectodomain shedding, and growth factor bioactivity.

Keywords

MMP - TIMP - lung development - ECM - remodeling

• References

• 1 Cardoso WV. Lung morphogenesis revisited: old facts, current ideas. Dev Dyn 2000; 219: 121-30.
• 2 Cardoso WV. Molecular regulation of lung development. Annu Rev Physiol 2001; 63: 471-94.
• 3 Burri PH. The postnatal growth of the rat lung. 3. Morphology. Anat Rec 1974; 180: 77-98.
• 4 Burri PH, Dbaly J, Weibel ER. The postnatal growth of the rat lung. I. Morphometry. Anat Rec 1974; 178: 711-30.
• 5 Jobe AH, Ikegami M. Lung development and function in preterm infants in the surfactant treatment era. Annu Rev Physiol 2000; 62: 825-46.
• 6 Warburton D, Schwarz M, Tefft D. et al. The molecular basis of lung morphogenesis. Mech Dev 2000; 92: 55-81.
• 7 Metzger RJ, Krasnow MA. Genetic control of branching morphogenesis. Science 1999; 284: 1635-9.
• 8 Cantor JO, Cerreta JM, Armand G. et al. The pulmonary matrix, glycosaminoglycans and pulmonary emphysema. Connect Tissue Res 1999; 40: 97-104.
• 9 Mays PK, McAnulty RJ, Campa JS. et al. Age-related changes in collagen synthesis and degradation in rat tissues. Importance of degradation of newly synthesized collagen in regulating collagen production. Biochem J 1991; 276 (Pt 2) 307-13.
• 10 Chen CS, Tan J, Tien J. Mechanotransduction at cell-matrix and cell-cell contacts. Annu Rev Biomed Eng 2004; 6: 275-302.
• 11 Rosso F, Giordano A, Barbarisi M. et al. From cell- ECM interactions to tissue engineering. J Cell Physiol 2004; 199: 174-80.
• 12 Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003; 200: 448-64.
• 13 Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463-516.
• 14 Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827-39.
• 15 Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11: S37-43.
• 16 Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002; 3: 409-21.
• 17 Winkler MK, Foldes JK, Bunn RC. et al. Implications for matrix metalloproteinases as modulators of pediatric lung disease. Am J Physiol Lung Cell Mol Physiol 2003; 284: L557-65.
• 18 Parks WC, Shapiro SD. Matrix metalloproteinases in lung biology. Respir Res 2001; 2: 10-9.
• 19 Parks WC. Matrix metalloproteinases in lung repair. Eur Respir J Suppl 2003; 44: 36s-38s.
• 20 Cederqvist K, Sorsa T, Tervahartiala T. et al. Matrix metalloproteinases-2, –8, and –9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress. Pediatrics 2001; 108: 686-92.
• 21 Fukuda Y, Ishizaki M, Okada Y. et al. Matrix metalloproteinases and tissue inhibitor of metalloproteinase- 2 in fetal rabbit lung. Am J Physiol Lung Cell Mol Physiol 2000; 279: L555-61.
• 22 Lemke RP, Zhang W, Balcerazak D. et al. Expression and activity of matrix metallo proteinases 2 and 9 and their inhibitors in rat lungs during the perinatal period and in diaphragmatic hernia. Exp Lung Res 2003; 29: 261-76.
• 23 Valencia AM, Beharry KD, Ang JG. et al. Early postnatal dexamethasone influences matrix metalloproteinase- 2 and –9, and their tissue inhibitors in the developing rat lung. Pediatr Pulmonol 2003; 35: 456-62.
• 24 Gebb SA, Jones PL. Hypoxia and lung branching morphogenesis. Adv Exp Med Biol 2003; 543: 117-25.
• 25 Vicencio AG, Eickelberg O, Stankewich MC. et al. Regulation of TGF-beta ligand and receptor expression in neonatal rat lungs exposed to chronic hypoxia. J Appl Physiol 2002; 93: 1123-30.
• 26 Selman M, Ruiz V, Cabrera S. et al. TIMP-1, –2, –3, and –4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?. Am J Physiol Lung Cell Mol Physiol 2000; 279: L562-74.
• 27 Pugin J, Widmer MC, Kossodo S. et al. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999; 20: 458-64.
• 28 Nuttall RK, Sampieri CL, Pennington CJ. et al. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett 2004; 563: 129-34.
• 29 Kuzuya M, Kanda S, Sasaki T. et al. Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation 2003; 108: 1375-81.
• 30 Zhuge Y, Xu J. Rac1 mediates type I collagen-dependent MMP-2 activation. role in cell invasion across collagen barrier. J Biol Chem 2001; 276: 16248-56.
• 31 Nabeshima K, Inoue T, Shimao Y. et al. Front-cellspecific expression of membrane-type 1 matrix metalloproteinase and gelatinase A during cohort migration of colon carcinoma cells induced by hepatocyte growth factor/scatter factor. Cancer Res 2000; 60: 3364-9.
• 32 Kheradmand F, Rishi K, Werb Z. Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2. J Cell Sci 2002; 115: 839-48.
• 33 Atkinson JJ, Holmbeck K, Yamada S. et al. Membrane- type 1 matrix metalloproteinase is required for normal alveolar development. Dev Dyn 2005; 232: 1079-90.
• 34 Oblander SA, Zhou Z, Galvez BG. et al. Distinctive functions of membrane type 1 matrix-metalloprotease (MT1-MMP or MMP-14) in lung and submandibular gland development are independent of its role in pro- MMP-2 activation. Dev Biol 2005; 277: 255-69.
• 35 Reponen P, Sahlberg C, Huhtala P. et al. Molecular cloning of murine 72-kDa type IV collagenase and its expression during mouse development. J Biol Chem 1992; 267: 7856-62.
• 36 Koshikawa N, Giannelli G, Cirulli V. et al. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol 2000; 148: 615-24.
• 37 Koshikawa N, Schenk S, Moeckel G. et al. Proteolytic processing of laminin-5 by MT1-MMP in tissues and its effects on epithelial cell morphology. Faseb J 2004; 18: 364-6.
• 38 Ekekezie II, Thibeault DW, Simon SD. et al. Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease. Pediatrics 2004; 113: 1709-14.
• 39 Sweet DG, Curley AE, Chesshyre E. et al. The role of matrix metalloproteinases –9 and –2 in development of neonatal chronic lung disease. Acta Paediatr 2004; 93: 791-6.
• 40 Leco KJ, Waterhouse P, Sanchez OH. et al. Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). J Clin Invest 2001; 108: 817-29.
• 41 Gill SE, Pape MC, Khokha R. et al. A null mutation for tissue inhibitor of metalloproteinases-3 (Timp-3) impairs murine bronchiole branching morphogenesis. Dev Biol 2003; 261: 313-23.
• 42 Amour A, Slocombe PM, Webster A. et al. TNFalpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435: 39-44.
• 43 Zhao J, Chen H, Peschon JJ. et al. Pulmonary hypoplasia in mice lacking tumor necrosis factor-alpha converting enzyme indicates an indispensable role for cell surface protein shedding during embryonic lung branching morphogenesis. Dev Biol 2001; 232: 204-18.
• 44 Patterson BC, Sang QA. Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 1997; 272: 28823-5.
• 45 Buckley S, Warburton D. Dynamics of metalloproteinase- 2 and –9, TGF-beta, and uPA activities during normoxic vs. hyperoxic alveolarization. Am J Physiol Lung Cell Mol Physiol 2002; 283: L747-54.
• 46 Hosford GE, Fang X, Olson DM. Hyperoxia decreases matrix metalloproteinase-9 and increases tissue inhibitor of matrix metalloproteinase-1 protein in the newborn rat lung: association with arrested alveolarization. Pediatr Res 2004; 56: 26-34.